Form 8-K - Current report:
SEC Accession No. 0001193125-26-218224
Filing Date
2026-05-12
Accepted
2026-05-12 08:00:07
Documents
13
Period of Report
2026-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d91737d8k.htm   iXBRL 8-K 23356
2 EX-99.1 d91737dex991.htm EX-99.1 45050
6 GRAPHIC g91737g0511235621743.jpg GRAPHIC 3960
  Complete submission text file 0001193125-26-218224.txt   196825

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tenx-20260512.xsd EX-101.SCH 3204
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20260512_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20260512_pre.xml EX-101.PRE 11277
16 EXTRACTED XBRL INSTANCE DOCUMENT d91737d8k_htm.xml XML 3643
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 26965922
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)